GSK today announced results from the BLISS-SC Phase III pivotal study in patients with active, autoantibody-positive systemic lupus erythematosus (SLE). These results ...
Subcutaneous injections are a method of administering medication just under the skin, between the fatty tissue and muscle. It allows medication to be absorbed slowly over a longer period of time.
-In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback